Retinoic Acid Negatively Impacts Proliferation and MCTC Specific Attributes of
Human Skin Derived Mast Cells, but Reinforces Allergic Stimulability by Babina, Magda et al.
 International Journal of 
Molecular Sciences
Article
Retinoic Acid Negatively Impacts Proliferation and
MCTC Specific Attributes of Human Skin Derived
Mast Cells, but Reinforces Allergic Stimulability
Magda Babina *, Metin Artuc, Sven Guhl and Torsten Zuberbier
Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany;
metin.artuc@charite.de (M.A.); sven.guhl@gmx.de (S.G.); torsten.zuberbier@charite.de (T.Z.)
* Correspondence: magda.babina@charite.de; Tel.: +49-30-45051-8408; Fax: +49-30-45051-8900
Academic Editor: Ge Zhang
Received: 16 November 2016; Accepted: 21 February 2017; Published: 28 February 2017
Abstract: The Vitamin-A-metabolite retinoic acid (RA) acts as a master regulator of cellular
programs. Mast cells (MCs) are primary effector cells of type-I-allergic reactions. We recently
uncovered that human cutaneous MCs are enriched with RA network components over other skin
cells. Yet, direct experimental evidence on the significance of the RA-MC axis is limited. Here,
skin-derived cultured MCs were exposed to RA for seven days and investigated by flow-cytometry
(BrdU incorporation, Annexin/PI, FcεRI), microscopy, RT-qPCR, histamine quantitation, protease
activity, and degranulation assays. We found that while MC size and granularity remained unchanged,
RA potently interfered with MC proliferation. Conversely, a modest survival-promoting effect from
RA was noted. The granule constituents, histamine and tryptase, remained unaffected, while RA
had a striking impact on MC chymase, whose expression dropped by gene and by peptidase activity.
The newly uncovered MRGPRX2 performed similarly to chymase. Intriguingly, RA fostered allergic
MC degranulation, in a way completely uncoupled from FcεRI expression, but it simultaneously
restricted MRGPRX2-triggered histamine release in agreement with the reduced receptor expression.
Vitamin-A-derived hormones thus re-shape skin-derived MCs numerically, phenotypically, and
functionally. A general theme emerges, implying RA to skew MCs towards processes associated with
(allergic) inflammation, while driving them away from the skin-imprinted MCTC (“MCs containing
tryptase and chymase”) signature (chymase, MRGPRX2). Collectively, MCs are substantial targets of
the skin retinoid network.
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1. Introduction
Mast cells (MCs), unique elements of the human body [1,2], are of hematopoietic origin, but
develop exclusively in target organs, such as the skin, and the intestinal or respiratory tracts,
respectively [3–5]. In humans, MCs are best understood for their role as effectors of IgE-mediated
allergic reactions and in the skin, as intermediaries of pruritus symptoms by interaction of MC derived
mediators with sensory nerves [6–8]. Accordingly, MCs are numerically increased and/or functionally
altered in skin conditions like atopic dermatitis, psoriasis and urticaria [9–11].
The skin is not only particularly rich in MCs even in the absence of infection or
inflammation [12–14], but it is also a firmly established target of Vitamin A derivatives, of which
the carboxylic acid form, all-trans retinoic acid (RA), represents the major hormonally active entity.
A tight association between the retinoid system and the skin is underscored by the amounts of RA
and its precursors found in this organ and the abundance of proteins involved in RA metabolism and
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function [15,16], and further substantiated by the broad therapeutic use of retinoids for skin disorders;
in fact, retinoid based therapies are inclined towards dermatological conditions [17–24].
So far, skin MCs have not been in the focus of cutaneous RA research. This may reflect the
fact that MC purification from skin is costly and laborious and the starting material not widely
accessible to researchers. We have overcome this hurdle, and routinely purify MCs from human skin
to homogeneity [1,13,25,26].
By interrogating the comprehensive FANTOM5 (Functional annotation of the mammalian
genome 5) expression atlas, which encompasses skin MCs from our laboratory [27], we surprisingly
found that it was MCs that expressed the highest levels of the most versatile retinoid receptor subtype
(RARA, retinoic acid receptor alpha) across the entire atlas [28]. The extensive coverage of the atlas with
nearly 1900 libraries from all parts of the body, including ~200 primary cells, as well as time-course
series [27,29], implied an important, yet largely overlooked connection between RA and skin MCs.
Following up on this theory, we found further evidence through bioinformatics analyses, pinpointing
skin MCs as highly enriched with genes pertinent to the retinoid network vis-à-vis other skin cell
subsets [28].
These findings spurred further interest in the modulatory effect exerted by RA in MCs from
the skin compartment. Focusing on RA’s role in mitogenesis, MC signature characteristics and
functional competence, we now report that RA has a profound impact on skin-derived MCs,
where it interferes with proliferation and selective attributes of the skin-dwelling MCTC subset,
while simultaneously promoting allergic, yet suppressing pseudo-allergic (MRGPRX2-driven) MC
degranulation. Collectively, our study substantiates a close connection between skin MCs and the
skin RA network and implies MCs as considerable elements in cutaneous retinoid biology under
homeostatic and therapeutic conditions.
2. Results
2.1. RA Counters Proliferation but Has No Negative Impact on the Survival of Human Skin-Derived MCs
Even though classified as terminally differentiated cells, tissue MCs can re-enter the cell cycle if
supported by sufficient amounts of stem cell factor (SCF), and this phenomenon also accounts to MCs
derived from human skin [30]. Under optimal conditions, the cells require 1–2 weeks to complete one
cycle of replication [26,30,31] and express cell cycle regulators like E2F1 and PCNA (proliferating cell
nuclear antigen) during this period [1,31].
Here we found that RA counteracted the SCF-driven increment in MC numbers (Figure 1A).
Addressing the mechanism, we detected that the proportion of Annexin+ (i.e., apoptotic) cells was not
increased but even slightly (yet significantly) diminished in the presence of RA (Figure 1B). This was
supported by the expression profile of selected genes, where anti-apoptotic Mcl-1 slightly increased,
while Bcl-xl as well as pro-apoptotic Bax remained unchanged by RA (Figure 1C).
Therefore, RA did obviously not act by triggering cell death in our system. We next tested whether
RA affected cell cycle progression of skin-derived MCs, and found that this was indeed the case.
Using BrdU incorporation to track DNA synthesis, an anti-proliferative effect of RA, i.e., interference
with SCF-driven cell cycle progression, was easily detected (Figure 1D,E). The anti-proliferative effect
was accompanied by changes in selected transcripts associated with the cell cycle. While RA did not
influence p21 levels in our system, it diminished PCNA and E2F1 expression (Figure 1F), two genes
whose activity correlates with cell cycle progression of skin-derived MCs [1,31].
The microscopic evaluation of toluidine blue stained MCs revealed intact granule architecture
in RA treated MCs (Figure 1G), and the cell size likewise remained unaffected in the presence of RA
(mean diameter 13.94 ± 0.21 µm for SCF alone, 13.96 ± 0.18 µm for RA), suggesting that SCF-mediated
cell growth was normal.
We conclude that the reduced increment in MC numbers in the presence of RA results from
interference with SCF-evoked proliferation, but not from reduced viability of non-cycling MCs.
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Figure 1. Retinoic acid (RA) inhibits cell cycle progression of skin-derived mast cells (MCs), but also 
modestly interferes with cell death. Cultured skin-derived MCs (at the proliferative stage) were 
treated with RA as described in the Experimental section and harvested after 7 days. (A) Increase in 
MC numbers (relative to day 0) in the presence versus absence of RA in a variety of donors, indicated 
by interconnected dots (n = 17); (B) Annexin+ cells (in % of total cells) after culture with and without 
RA, mean ± SEM, n = 5; (C) Expression of apoptosis related genes in RA treated cells normalized to 
the “no RA” control, mean ± SEM, n = 9, dotted line drawn at 1 to highlight control expression (in the 
absence of RA); (D,E) BrdU incorporation (added 5 days before harvest), as determined by 
flow-cytometry, (D) representative example, (E) mean ± SEM of n = 7; (F) Expression of cell cycle 
associated genes in RA treated cells normalized to the “no RA” control, mean ± SEM, n = 9; (G) 
Visualization of MCs upon acidic toluidine blue staining reveals no conspicuous changes by RA; 
note the bright purple granules and the accumulation of cytoplasm, the latter typical of MCs exposed 
to SCF; (A,B,E) Paired t-test, (C,F) one-sample t-test versus control (set as 1). * p < 0.05; ** p < 0.01, *** p 
< 0.001, **** p < 0.0001 versus control. 
2.2. Granule Constituents 
MC granules are filled with an array of preformed mediators (especially histamine, heparin, 
and MC specific proteases) and represent the most salient feature of the lineage (see Figure 1G). 
Accordingly, transcripts for the granule-associated proteases tryptase and chymase are among the 
most abundant and specific MC signature genes [1,32,33]. Histamine, on the other hand, mediates 
many of the clinical symptoms resulting from allergic MC activation and is therefore a major target 
of anti-allergic medication. 
We assessed whether RA modulated cellular histamine accumulation and expression of 
L-histidine decarboxylase (HDC), the enzyme catalyzing the rate-limiting step in histamine 
formation. Both HDC mRNA and histamine contents remained comparable in cells exposed to RA 
versus cells kept in SCF alone (Figure 2A,B, left), even though there was a tendency of increased 
expression in the case of HDC gene expression (Figure 2A, left). 
Focusing on MC specific proteases, we found that tryptase mRNA was dampened by RA, 
whereas tryptase activity remained comparable between the groups (Figure 2A,B, middle). 
Conversely, chymase mRNA experienced a highly significant drop in the presence of RA down to 






















































































































































Figure 1. Retino c a id (RA) inhibits cel c gre sion of skin-derived mast cells (MCs), but also
modestly interferes with cell death. Cultured skin-derived MCs (at the proliferative stage) wer treated
with RA as described in the Experimental section and harvested after 7 days. (A) Increase in MC
numbers (relative to day 0) in the presence versus absence of RA in a variety of donors, indicated by
interconnected dots (n = 17); (B) Annexin+ cells (in % of total cells) after culture with and without RA,
mean ± SEM, n = 5; (C) Expression of apoptosis related genes in RA treated cells normalized to the “no
RA” control, mean ± SEM, n = 9, dotted line drawn at 1 to highlight control expression (in the absence
of RA); (D,E) BrdU incorporation (added 5 days before harvest), as determined by flow-cytometry,
(D) representative example, (E) mean ± SEM of n = 7; (F) Expression of cell cycle associated genes in
RA treated cells normalized to the “no RA” control, mean ± SEM, n = 9; (G) Visualization of MCs
upon acidic toluidine blue staining reveals no conspicuous chang s by RA; note the bright purple
granules and the accumulation of cytopl sm, the latt typical f MCs exposed to SCF; (A,B,E) Paired
t-test, (C,F) one-sample t-test versus control (set as 1). * p < 0.05; ** p < 0.01, *** p < 0.001, **** p < 0.0001
versus control.
2.2. Granule Constituents
MC granules are filled with an array of preformed mediators (especially histamine, heparin,
and MC specific proteases) and represent the most salient feature of the lineage (see Figure 1G).
Accordingly, transcripts for the granule-associat d prote ses trypt se and chymase re among the
most abundant and spec fic MC signature genes [1,32,33]. Histamine, on the other hand, mediates
many of the clinical symptoms resulting from allergic MC activation and is therefore a major target of
anti-allergic medication.
We assessed whether RA modulated cellular histamine accumulation and expression of L-histidine
decarboxylase (HDC), the enzyme catalyzing the rate-limiting step in histamine formation. Both HDC
mRNA and histamine contents remained comparable in cells exposed to RA versus cells kept in SCF
alone (Figure 2A,B, left), even though there was a tendency of increased expression in the case of HDC
gene expression (Figure 2A, left).
Focusing on MC specific proteases, we found that tryptas mRNA was dampened by RA, whereas
tryptase activity remained comparable between the groups (Figure 2A,B, middle). Conversely, chymase
mRNA experienced a highly significant drop in the presence of RA down to approximately one third
(34.7%) of control expression (Figure 2A, middle). This was accompanied by reduced chymase activity,
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which showed the same tendency, even though the effect was less pronounced (decrease to 70.8% by
mean, and to 66.7% by median of control) (Figure 2B, middle).
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Figure 2. Granule-associated mediators: RA dampens chymase mRNA and chymase activity. (A) 
Relative mRNA expression of histidine decarboxylase (HDC, involved in histamine generation), 
tryptase and chymase normalized to β actin, respectively, in RA treated and control cells (mean ± 
SEM, n = 9); (B) Mediator contents. Histamine was quantified by an auto-analyzer based method, 
while tryptase and chymase activity were measured by cleavage of specific substrates in RA 
pretreated and control cells, as described in the Experimental section. Each dot corresponds to one 
MC preparation and dots representing the same donor are connected. n = 11 (histamine) or 9 
(tryptase, chymase). ** p < 0.01, *** p < 0.001 versus control (by paired t-test). 
Collectively, RA does not impact the preformed mediators histamine and tryptase in our 
system. Intriguingly, however, there is a particularly clear (negative) effect on MC chymase, a 
selective marker of the MCTC subcategory, i.e., MCs containing tryptase and chymase (the subset 
found in the skin over MCT cells, which only contain tryptase and predominate in the lung or gut). 
2.3. FcεRI Expression and Allergic MC Stimulation 
FcεRI, the high affinity receptor for IgE (IgER), represents a classical functional unit of MCs and 
has been investigated thoroughly for its role in type-I allergic reactions [6,8]. In the present study, 
cell surface level of FcεRIα remained unchanged in the presence of RA, even though there was a 
tendency towards downregulated expression (Figure 3A,B). When studying the impact of RA on 
FcεRI-triggered degranulation responses, we found that histamine release was fostered by prior RA 
treatment. In fact, a heightened release was detected in 12 out of 14 samples (donors), while one 
preparation showed the opposite trend and another one no impact from RA. Despite the divergent 
preparation statistical probability was p < 0.01 (Figure 3C, right), which rose to p < 0.0001 without the 
deviating sample (not illustrated). In contrast, blank histamine release (i.e., release in the absence of 
a specific stimulus) showed no tendency in any direction and both down- and up-regulations were 
common (Figure 3C, left). Note that the spontaneous release is manifoldly lower than the release 
elicited by FcεRI aggregation (different scale on the y-axis) and also has a greater error rate. In Figure 
Figure 2. Granule-associated mediators: RA dampens chymase mRNA and chymase activity.
(A) Relative mRNA expression of histidine decarboxylase (HDC, involved in histamine generation),
tryptase and chymase normalized to β actin, respectively, in RA treated and control cells (mean ± SEM,
n = 9); (B) Mediator contents. Histamine was quantified by an auto-analyzer based method, while
tryptase and chymase activity were measured by cleavage of specific substrates in RA pretreated and
control cells, as described in the Experimental section. Each dot corresponds to one MC preparation
and dots representing the same donor are connected. n = 11 (histamine) or 9 (tryptase, chymase).
** p < 0.01, *** p < 0.001 versus control (by paired t-test).
Collectively, RA does not impact the preformed mediators histamine and tryptase in our system.
Intriguingly, however, there is a particularly clear (negative) effect on MC chymase, a selective marker
of the MCTC subcategory, i.e., MCs containing tryptase and chymase (the subset found in the skin over
MCT cells, which only contain tryptase and predominate in the lung or gut).
2.3. FcεRI Expression and Allergic MC Stimulation
FcεRI, the high affinity rec ptor for IgE (IgER), represents a classical fu cti nal unit of MCs and
has been investigated thoroughly for its role in type-I allergic reactions [6,8]. In the present study,
cell surface level of FcεRIα remained unchanged in the presence of RA, even though there was a
tendency towards downregulated expression (Figure 3A,B). When studying the impact of RA on
FcεRI-triggered degranulation responses, we found that histamine release was fostered by prior RA
treatment. In fact, a heightened release was detected in 12 out of 14 samples (donors), while one
preparation showed the opposite trend and another one no impact from RA. Despite the divergent
preparation statistical probability was p < 0.01 (Figure 3C, right), which rose to p < 0.0001 without the
deviat ng sample (not illustrate ). In contrast, blank histamine release (i.e., elease in the absence of
a specific stimulus) showed no tendency in any direction and both down- and up-regulations were
common (Figure 3C, left). Note that the spontaneous release is manifoldly lower than the release
elicited by FcεRI aggregation (different scale on the y-axis) and also has a greater error rate. In Figure 3C
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(right), the spontaneous release was already subtracted from the gross histamine release obtained for
IgER stimulated cells (i.e., the net values are given in the figure, as detailed in the experimental section).
Histamine exteriorization under SCF saturation is very pronounced [26,31], reaching up to 77% of
the total cellular histamine content in control cells of the current dataset (Figure 3C). Because of this,
there does not seem to be much room for further intensification, and the fact that RA can actually do
this and drive degranulation further up seemed quite remarkable. We therefore asked whether RA’s
positive impact on IgER-triggered degranulation was dependent on the strength of the signal. Varying
the cross-linking agent over a range of 100-fold, we found a clearly supportive effect at the high and
intermediate cross-linking strength, confirming the results shown in Figure 3C by an independent set
of MC preparations (Figure 3D). At the lowest signal strength, however, RA pre-treatment reduced
degranulation, and this resulted in a changed dose-response curve for RA-treated versus control MCs
with a steeper increase between 0.005 and 0.05 µg/mL in the former (Figure 3D).
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example, (B) cumulative data from n = 8 MC preparations; MFI = Mean fluorescence intensity; (C) 
Left, Histamine release in the absence of a specific stimulus (spontaneous) in % of the complete 
cellular histamine present in the respective MC preparation; right, net histamine release specifically 
elicited by FcεRI-aggregation (note that spontaneous release, determined for each preparation, was 
subtracted from the corresponding value after FcεRI-triggering) in RA pretreated and control MCs. n 
= 14; (B,C) Each dot corresponds to one MC preparation and dots representing the same donor are 
connected; (D) Dose-response of histamine release in RA pretreated and control cells triggered by 
different concentrations of the IgER-aggregating antibody 29C6, experiment as in (C) but using 
another set of MC preparations and other concentrations, n = 7. (E) Relative mRNA expression of the 
three chains forming the FcεRI complex normalized to β actin (mean ± SEM, n = 9). * p < 0.05, ** p < 
0.01, **** p < 0.0001 significantly higher than control, + p < 0.05 significantly lower than control; ns = 
not significant. 
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Figure 3. RA reinforces FcεRI-mediated degranulation, but has no effect on the expression of the
FcεRI receptor complex. (A,B) FcεRI cell surface expression by flow-cytometry; (A) Representative
example, (B) cumulative data from n = 8 MC preparations; MFI = Mean fluorescence intensity; (C) Left,
Histamine release in the absence of a specific stimulus (spontaneous) in % of the complete cellular
histamine present in the respective MC preparation; right, net histamine release specifically elicited by
FcεRI-aggregati n (note that spo taneous r lease, determi ed for each preparation, was subtracted
from the correspon ing value after FcεRI-triggering) in RA pretreat d and control MCs. n = 14;
(B,C) Each dot correspond t one MC preparation and dots r pres nting the same donor are connected;
(D) Dose-response of histamine release in RA pretreated and control cells triggered by different
concentrations of the IgER-aggregating antibody 29C6, experiment as in (C) but using another set of MC
preparations and other concentrations, n = 7. (E) Relative mRNA expression of the three chains forming
the FcεRI complex normalized to β actin (mean ± SEM, n = 9). * p < 0.05, ** p < 0.01, **** p < 0.0001
significantly higher than control, + p < 0.05 significantly lower than control; ns = not significant.
The IgER complex is expressed as a tetramer consisting of three subunits in the composition of
αβγ2, where the α chain (protruding from the cell surface) is responsible for IgE binding, while the
β and γ chains (the former not absolutely required for complex formation) are involved in signal
transduction [34]. By quantitative RT-PCR, α, β and γ specific transcripts remained unchanged in
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the presence of RA (Figure 3E), largely in accordance with the protein expression data depicted in
Figure 3A,B. We conclude that RA stimulates allergic MC activation via the FcεRI complex if the
cross-linking efficiency is sufficiently pronounced. This occurs without altered expression of the IgER
complex, but by reinforced releasability via the IgER complex.
2.4. Other MC Selective Traits
The availability of the comprehensive body-wide expression atlas pinpointed MCs as unique
cellular elements of the body and identified additional genes with MC restricted or MC enriched
expression. Two examples among the uncovered MC “private genes” are T1/ST2 (IL1RL1) and
MRGPRX2 [1], the former encoding the IL-33 receptor [35], the latter a G protein coupled receptor
mediating so-called “pseudo-allergic” reactions [36]. Here, we investigated their modulation by RA.
CD43 (SPN), earlier reported to be an RA-responsive gene in MCs [28,37], served as positive control,
and was confirmed to also be promoted by RA in the current study (Figure 4A). ST2/T1 as well
as MRGPRX2 were robustly expressed by MCs (Figure 4B,C showing expression against the highly
expressed β actin gene) but not by other cell subsets (like dermal fibroblasts and several cell lines, not
depicted), substantiating the results from FANTOM5 [1]. T1/ST2 gene expression remained unaffected
in the presence of RA (Figure 4B). In contrast, MRGPRX2 expression substantially diminished after RA
treatment down to 34.8% (Figure 4C), thereby duplicating the effect on MC chymase. MRGPRX2 is
the long-sought receptor for compound 48/80, a typical MC secretagogue able to degranulate MCs of
skin origin [36]. We therefore asked whether its decreased expression in RA-treated cells would be
mirrored at the functional level. This was clearly found to be the case, and compound 48/80-triggered
degranulation was reduced by RA pretreatment in each MC preparation tested (Figure 4D).
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Figure 4. Impact of RA on other genes and MC-restricted processes. Relative mRNA expression,
normalized to β actin, for (A) the pan-he ato oieti i l i (t e lat er used as control of an
RA-upregulated gene); (B) the IL-33 receptor ST2/T1, and (C) the MC-sel ctive rec ptor MRGPRX2,
Mean ± SEM, = 9; (D) et histamine release licit d by MRGPRX2 triggering (by use of its agonist
compound 48/80 at 10 µg/mL) in RA pretreated and control MCs (analogous to Figure 3C,D).
n = 12. Each dot corresponds to one MC preparation and dots t e same donor are
co nected. ** p < 0.01, < 0.001, * p < 0. 0 1 significantly different from contr l (by paired t-test);
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3. Discussion
Vitamin A derivatives such as RA have long been known for their wide-range of effects in
embryonic development and tissue homeostasis alike, where retinoid receptors impinge on gene
expression programs by binding as heterodimers to retinoic acid response elements in target genes to
regulate multiple cellular functions [38–40].
RA has a particularly profound impact on skin biology. In fact, the skin endogenously produces
substantial amounts of RA and its precursors (such as retinol) that contribute to the maintenance of
skin homeostasis [16], while therapeutically applied retinoids represent approved (topical or oral)
treatments for a wide range of skin disorders including psoriasis, acne, photoaging, non-melanoma
skin cancer, cutaneous T-cell lymphomas, ichthyosis, as well as chronic hand eczema, and they even
form part of cosmetic products [17–24].
So far, the focus of cutaneous RA research was inclined towards keratinocytes and fibroblasts,
while cutaneous MCs have not been considered major participants in the retinoid system of the
skin. Moreover, studies that did focus on the retinoid-MC connection rarely employed MCs of skin
origin [37,41–44]. However, MC heterogeneity is a well-known phenomenon, where representatives of
the lineage display variability across species, tissues, and microenvironments. It therefore came as a
surprise that a cell, which had received fairly little attention with regard to the cutaneous Vitamin A
system, turned out a more important partaker than envisaged thus far [28]. This fostered our interest in
the impact imposed by RA on MCs in human skin, complementing earlier reports on RA’s modulation
of adhesion molecules and selected differentiation markers, performed chiefly on immature MC lines
and in vitro generated MC progenitors [37,41–44].
To gain insight into RA’s modulatory activity in MCs of skin origin, the current study was
designed to investigate a reasonable spectrum of processes, encompassing basic cellular functions
(like survival and proliferation), as well as MC-specific programs like granule constituent accumulation
and allergic as well as pseudo-allergic MC degranulation, with the result that RA indeed impacts
functional competence of skin-derived MCs.
We first focused on cell cycle progression and cell viability, two fundamental and tightly regulated
processes of every cell subset. There is abundant evidence in the literature demonstrating that RA can
either enhance or counter mitogenesis depending on cell type and context. In our system, a considerable
anti-proliferative action of RA was detected by BrdU incorporation, and this was reflected by changes
in cell cycle regulators like PCNA and E2F1, both of which associated with the proliferative state of
human skin-derived MCs [1,31]. In contrast, we did not observe any modulation in p21 expression, a
gene frequently up-regulated by RA in a variety of leukemic cells [45,46]. Together, this implies that
the mechanisms by which RA inhibits mitogenesis are cell-type specific. The anti-proliferative activity
detected here for non-transformed skin-derived MCs is consistent with RA-induced cell cycle arrest
in leukemia cells, including cells of the human MC line HMC-1 [47,48], as well as in hematopoietic
progenitor-derived MCs [43,44]. The combined evidence now indicates that RA interference with MC
proliferation occurs in a manner that is largely independent of the precise nature of the MCs (leukemic
versus normal, slowly or rapidly dividing, tissue or precursor-derived). Contrary to the inhibited
proliferation, RA had no negative impact on MC survival, where even a modest anti-apoptotic effect
was revealed. An uncoupling between proliferation and survival, yet in the opposite direction, was
previously reported for myeloid progenitors, where increased growth by RA was associated with
decreased survival [49].
Collectively, in cycling MCs, RA will counter cell increments by decelerating cell cycle progression,
while under conditions in which no (major) proliferation occurs, the MC compartment will unlikely
experience major numerical changes by RA, or else survival will even be enhanced, as was also
evidenced in a previous study [44].
In terms of MC-restricted attributes and processes, one finding was that no conspicuous changes
occurred in RA treated MCs on microscopic inspection upon staining with toluidine blue, a MC
selective dye (Figure 1G). This applied to cell size and the MC-specific granules alike, suggesting that
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heparin synthesis and overall granule architecture were preserved in the presence of RA. Assessing
granule constituents one by one, the finer level of resolution revealed several additional aspects. Here,
histamine and tryptase abundance remained unchanged, while chymase experienced a robust and
selective drop.
Considering mRNA and mediator levels simultaneously, we found that while tryptase was
resistant to alterations at the activity level, there was significant reduction at the mRNA level.
The discordance between tryptase mRNA and the corresponding peptidase activity has been observed
previously and applies to MCs across donors [13], MCs skewed by IL-4 [26] as well as MCs exposed to
IL-33 [50]. The bottom line from the different studies combined is that the predictive value of tryptase
mRNA for the active protein is low. The current study substantiates this notion. In our previous report,
histamine levels were positively linked to tryptase activity, suggesting that the amount of histamine
in the granule may partially dictate tryptase abundance [13]. This is supported by findings in the
mouse, as HDC−/− mice (that do not produce histamine) have profound defects in the accumulation
of several MC proteases despite normal mRNA levels [51]. Because histamine levels were unchanged
in RA-treated cells, it may be speculated that histamine is the critical component in maintaining the
amount of active tryptase.
On the other hand, there is better, but far from absolute concordance between mRNA and
protein in the case of chymase, where chymase mRNA typically shows the same tendency as chymase
activity [13,26], and this was also detected here. In addition, in our population-based study, chymase
activity was also positively associated with histamine abundance (yet the strength of the correlation
between histamine and chymase was lower than between histamine and tryptase) [13]. The current
data further substantiate that mRNA of these highly lineage-specific traits is a necessary but not
sufficient prerequisite for the appearance of the functional peptidase products, and that other variables
are important, one of which may be the abundance of histamine. Notwithstanding, the chymase gene
may serve as a prototypical gene to establish the molecular background by which MCs in the skin
acquire their selective MCTC signature and how RA interferes with this process.
Our data may also provide some interpretation on a previous study, in which MCs were
enumerated in human skin exposed to topical RA treatment for up to six weeks [44]. In that work,
Hjertson and colleagues found an increase in MCT (“MCs containing only tryptase”) MCs in the
skin treated with RA cream (which are virtually absent from the skin under normal conditions),
while no increase was found for the chymase containing MCTC subset. Our current findings offer an
explanation, namely that the de novo appearance of MCT MCs in RA treated skin may result from the
down-regulated chymase expression, becoming undetectable to immunohistochemistry. The increase
in MCs (of the MCT category) after RA treatment implies that RA has a survival-promoting role in
MCs embedded in their natural habitat, which would also be compatible with the present study.
Addressing RA’s impact on the most thoroughly investigated and clinically relevant MC process,
i.e., allergic stimulation, the current study revealed that RA unexpectedly, but discernibly promoted
degranulation responses triggered by FcεRI cross-linking. Of note, there was a simultaneous tendency
towards reduced FcεRI expression together with the increased FcεRI functionality. This finding adds to
the growing appreciation that IgER expression and IgER-triggered degranulation represent uncoupled
qualities of MCs ([13] and references therein). Taken together, RA fosters allergic degranulation by a
route independent of enhanced FcεRI expression. The process of FcεRI-elicited exocytosis is highly
complex and involves not only numerous signaling intermediates, but also a diverse set of accessory
proteins which organize traffic, priming, tethering and docking of secretory vesicles, such as members
of the Rab, Munc13, and Munc18 families, and especially Ca2+ sensors like synaptotagmins and
other Ca2+ acceptors [52]. RA may influence several of these molecules in different directions, which
would be compatible with the finding that at low cross-linking efficiency, inhibition of FcεRI-elicited
exocytosis by RA prevails (Figure 3D). From an allergy-centered view the globally rather increased
propensity of RA-exposed MCs to exocytosis implies a pro-allergic role of RA at the level of the skin
MC, at least in situations in which specific IgE and allergen are intermediate to abundant.
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A rather pro-allergic or generally pro-inflammatory function of RA in skin MCs is further
supported by our previous observation of strengthened cytokine responses in response to RA [28],
and earlier studies showing increased expression of adhesion molecules in (mainly leukemic)
MCs [37,41,42]. This view also fits the finding of RA-mediated attraction of T cells not only to mucosal
tissues but also to inflamed sites, supportive of a rather inflammation-promoting or -maintaining
function of RA [53]. Collectively, the combined data imply that the overall effect of RA on skin
MCs is highly gene and process-specific. While MCs seem to adopt a more inflammatory role in the
presence of RA, RA apparently drives MCs away from their cutaneous signature. This is based on
the finding that RA dampens the “classical” marker of the MCTC subset, i.e., MC chymase. In fact,
chymase is a strong criterion of skin MC maturity, because other lineage attributes (including FcεRI
and HDC) are also expressed in more immature MCs [54]. This may signify a partially dedifferentiating
effect of RA on MCs away from the phenotype imprinted by the surrounding dermal compartment.
In further agreement with this notion, RA has a negative impact on MRGPRX2 expression, the receptor
for several neuropeptides as well as pseudo-allergic reactions (the latter triggered by a variety of
drugs) [36,55]. In fact, using the MRGPRX2 agonist compound 48/80, we directly demonstrate that RA
blunts responses to this MCTC-related G protein coupled receptor, matching RA’s impact on MRGPRX2
expression (Figure 4D). Like MC chymase, MRGPRX2 seems to be confined to MCs in skin tissue, as
MCs of mucosal tissues, including lung (a prototypical member of the MCT type) lack discernible
MRGPRX2 expression [56,57].
From a degranulation standpoint, our study revealed an opposite effect of RA on the two major
routes of MC degranulation, namely the allergic and the pseudo-allergic pathway. Through a series
of elegant experiments, it was recently reported that the two pathways differ quite profoundly
regarding signaling prerequisites, dynamics, and granule characteristics [58]. While IgER-triggered
degranulation is delayed and shows a progressive pattern, MRGPRX2-mediated degranulation is
rapid and associated with a quick and transient peak of intracellular calcium that is rapidly followed
by secretion of individual secretory granules. The IgER-elicited pattern depends on IKK-β activation
and SNAP23/STX4 complex formation, processes which are implicated in organizing the so-called
compound exocytosis, in which several granules fuse together [58]. We show that RA differentially
affects the pathways, favoring allergic degranulation via IgER-triggering, while simultaneously
inhibiting the pseudo-allergic route.
Together, RA has pleiotropic effects on MCs and seems to operate by different routes in the lineage,
on one hand by increasing several immune functions, in which MCs participate, but which are not
restricted to the lineage, such as generation of pro-inflammatory cytokines [28], but on the other by
reducing the most specific genes and processes of the skin-associated MCTC type.
It may seem counterintuitive that a molecule like RA with its deep connection to skin physiology
would counter the expression of MC lineage markers that are skin-specific. It is likely, though, that
the expression of each biomolecule is a finely tuned process consisting of positive and negative
regulatory circuits. So, even though the skin habitat does provide a MCTC-friendly environment, RA
may constitute a counter-balancing regulator in this setting. Of note, both chymase and MRGPRX2 are
still expressed in skin-derived MCs even after exposure to an RA-rich microenvironment, while they
are entirely absent from the mucosa of the intestinal and respiratory tract, respectively. It therefore
seems unlikely that the lack of MCTC marker expression in mucosal tissues primarily stems from the
presence of RA (even though RA plays a critical role in mucosal immunity and can redirect immune
cells to the gut [53,59]), but rather that the constellation of transcription factors and epigenetic attributes
may be favorable in the skin over mucosal tissues to permit chymase and MRGPRX2 transcription
in the first place. Revealing the molecular prerequisites behind MCTC specific features is actually an
important future challenge in the MC field, and the observations made in this study may actually help
in identifying the mechanistic details.
Other important future directions will include the dissection of RA-mediated responses in skin
MCs in different microenvironments, which by themselves shift MC phenotypes (e.g., IL-4 and
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IL-33 [26,50]), because it is clear from studies on hematopoietic stem cells that diverse and even
opposing effects can occur in dependence of the growth factors present [38,49]. Of note, the adaptive
immune system is under substantial influence from RA. For example, RA can skew T helper cell
subsets, in particular by supporting Foxp3+ regulatory T cell populations, while simultaneously
suppressing Th17 cells [53,59], and RA imprints gut homing in these subsets [53,59]. RA can also
modify Th1/Th2 subsets [53], and impact on B cell mediated immunity by fostering antibody-secreting
cells producing the IgA isotype [60]. Considering that MCs interact with T cells and are influenced
by their cytokines, MCs in the skin may not only be influenced directly (as is the focus of the current
report), but also indirectly via RA’s effects on the adaptive immune system. It will therefore be of quite
some interest to study the effect of RA on MCs embedded in skin equivalents like the organotypic
co-culture skin model developed and refined by our group over many years [61,62] to comprehend
RA’s role in MC communication with other resident skin cells (fibroblasts, keratinocytes), as well as
other immune constituents like T cells.
While the complexity of RA activity in the stem cell compartment has been recognized and
cataloged [38], we are at the beginning of dissecting RA’s impact on the MC lineage, a cell enriched with
retinoid network components [28] that shares features with hematopoietic stem cells [1]. The current
study provides further evidence that MCs are indeed relevant targets of the retinoid network and
should be considered in research of cutaneous retinoid biology.
4. Experimental Section
4.1. Isolation and Culture of Human Skin MCs
MCs were isolated from human breast skin as described [25] with slight modifications given in
recent publications [1,31,63]. The skin was obtained from cosmetic breast reduction surgeries, with the
informed consent of the patients and approval by the university ethics committee. The experiments
were conducted according to the Declaration of Helsinki Principles. Skin-derived MCs were expanded
in basal Iscove’s Medium (with 10% FCS, 100 U/mL Penicillin, 100 µg/mL Streptomycin, 2 mM
L-Glutamine, 1% nonessential amino acid solution, all from Biochrom, Berlin, Germany), and stem cell
factor (SCF) at 100 ng/mL (Peprotech, Hamburg, Germany), as described [26], as a modification of a
previously published procedure [30]. The cells were used for the experiments described herein after
3–5 weeks, i.e., at a stage when proliferation is detectable in MCs from all donors [31].
4.2. MC Treatment
MCs were kept at 5 × 105/mL in the presence or absence of RA (Sigma-Aldrich, Taufkirchen,
Germany) at 100 nM for a total of 7 days. RA was provided on days 0, 2, and 4, while SCF (100 ng/mL)
was provided on days 0 and 4 to maintain optimal growth, proliferation, and survival. MCs were
automatically counted by the CASY-TTC and their mean diameter was recorded (Innovatis/Casy
Technology, Reutlingen, Germany) [26,31,63].
4.3. Toluidine-Blue Staining and Microscopy
MC granules were specifically stained with acidic toluidine-blue (0.1% in 0.5 N HCl), and stained
MCs were photographed using a Zeiss Axiovert 10 microscope and a Canon power shot-A620 digital
camera, as described [31,63]. The original magnification was 400×.
4.4. Annexin-FITC/PI Staining
MCs were stained by the Annexin V-FITC Apoptosis detection kit (eBioscience, San Diego, CA,
USA) according to the manufacturer’s instructions and then analyzed by flow-cytometry on a Facscalibur
flow-cytometer device (BD Biosciences, Heidelberg, Germany). Annexin-V/PI-double-negative cells
were considered alive, while Annexin-V-positive cells were considered apoptotic (Annexin-V-single
positive—early apoptotic; Annexin-V-/PI-double positive—late apoptotic), as per instructions.
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4.5. BrdU Incorporation
DNA duplication was assessed with the BrdU flow kit (BD Pharmingen, Heidelberg, Germany)
according to the vendor’s instructions and as described previously for skin-derived MCs [30,31].
In brief, MCs were kept in the presence (or absence for control) of 10 µM BrdU for 5 days prior to
harvest and assayed for incorporation of BrdU using anti-BrdU-FITC and flow-cytometry.
4.6. Reverse Transcription-Quantitative PCR (RT-qPCR)
RT-qPCR was performed using optimized conditions and primer pairs described elsewhere [13,31,64].
Values were normalized to the housekeeping gene β-actin.
4.7. FcεRI Surface Expression
Flow-cytometry was performed as described [13,31]. The antibody used was anti-human
FcεRIα-PE at 2.5 µg/mL (clone AER-37, eBioscience, San Diego, CA, USA); mouse IgG2b-PE (clone
eBWG2b, eBioscience) served as isotype control.
4.8. Histamine Quantitation
Histamine was quantitated by an automated fluorescence method using an autoanalyzer
(Borgwald Technik, Hamburg, Germany), exactly as described [13,31]. All determinations
were performed in triplicate and histamine concentrations were calculated with reference to a
standard curve.
4.9. Histamine Release Assay
MCs were tested for degranulation responses (histamine release) following FcεRI-aggregation
(using the anti-FcεRIα-Ab 29C6 at 0.25 µg/mL for single-dose or 0.005, 0.05 and 0.5 µg/mL for
the dose-response experiments), compound 48/80 at 10 µg/mL (Sigma-Aldrich) or no stimulus for
spontaneous release. The assays were performed exactly as described and the net histamine release
(%) was calculated as [(stimulated release − spontaneous release)/complete histamine present in the
MC preparation] × 100 [13,26,31].
4.10. MC Protease Activity
Tryptase and chymase activities were quantified according to our routine protocols [13,31,54]
established upon previous publications [65].
4.11. Statistics
Differences between groups were assessed by paired or ratio paired t-test, or (when not normally
distributed) by Wilcoxon matched-pairs signed rank test with the program GraphPad-Prism, San Diego,
CA, USA. p < 0.05 was considered statistically significant. The number of independent experiments
performed for each assay is given in the respective figure legends as n.
5. Conclusions
The study supports the theory that MCs in human skin are highly relevant targets of Vitamin
A metabolites and that RA executes a program in these cells that is oriented towards more general
pan-hematopoietic and inflammatory programs while minimizing processes selective for the MCTC
subset that prevails in human skin. We expect that transcriptional and functional programs of MCs
may experience other profound modulations by RA, calling for a need of further research in the future.
Given that retinoids act as important developmental switches, and that retinoid receptors regulate a
plethora of genes, the accumulation of retinoid network components in MCs, as recently revealed [28],
is of relevance to fields as diverse as vitamin A research, MC biology, and skin (patho-)physiology alike.
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